

**JOINT STOCK COMPANY
DANANG PHARMACEUTICAL –
MEDICAL EQUIPMENT**

No.: 1528/TB-CT

**SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness**

Da Nang, October 20, 2025

*“Re: Explanation of post-tax profit
fluctuations in Q3/2025 financial statements
and accumulated for the first nine months of
2025 compared to the same period last year”*

**To: - State Securities Commission of Vietnam;
- Hanoi Stock Exchange.**

**1. Company name: Danang Pharmaceutical – Medical Equipment Joint Stock
Company**

2. Stock code: DDN (Upcom)

3. Head office: 02 Phan Dinh Phung, Hai Chau Ward, Danang City

4. Telephone: 0236.3822247 Fax: 0236.3891752

Published information content:

Pursuant to Circular No. 96/2020/TT-BTC dated November 16, 2020, Danang Pharmaceutical – Medical Equipment Joint Stock Company hereby provides the following explanation:

Profit after corporate income tax (CIT) on the Q3/2025 financial statements and the accumulated results for the first nine months of 2025 have changed by 10% or more compared to the same period of the previous year's report:

| Indicator | Year 2025 | Same period 2024 | Difference (%) |
|---------------------------------------------------|-------------------|-------------------------|-----------------------|
| Profit after CIT for Q3/2025 | 758,040,856 VND | 5,755,688,597 VND | -86.8% |
| Accumulated profit after CIT for 9 months of 2025 | 2,024,475,528 VND | 10,259,312,944 VND | -80.3% |

Details:

Profit after corporate income tax (CIT) for Q3/2025 and the accumulated results for the first nine months of 2025 decreased by 86.8% and 80.3%, respectively, compared to the same period in 2024. This is because, in the first nine months of 2024, the Company recorded income from the liquidation of unused accounts, while in 2025, the Company has been investing in the NeoVita Vaccination and Medical Service Center system in Ho Chi Minh City.

Recipients:

- As above;
- Company website;
- Filed at Office.

GENERAL DIRECTOR



NGUYEN LUONG TAM